Lineage Cell Therapeutics (LCTX) Current Leases (2014 - 2026)
Lineage Cell Therapeutics posted quarterly Current Leases of $833000.0 for Q1 2026, down 25.89% year-on-year from $1.1 million in Q1 2025, and up 2151.35% on a QoQ basis from $37000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) has 13 years of Current Leases data on file, last reported at $833000.0 in Q1 2026.
- For the quarter ending Q1 2026, Current Leases fell 25.89% year-over-year to $833000.0; the trailing twelve-month figure through Mar 2026 stood at $833000.0 (down 25.89% YoY), and the FY2025 full-year result was $37000.0, down 32.73% from the prior year.
- Current Leases for Q1 2026 stood at $833000.0, up from $37000.0 in the prior quarter.
- Across five years, Current Leases topped out at $1.1 million in Q1 2025 and bottomed at $29000.0 in Q2 2022.
- The 5-year median for Current Leases is $54000.0 (2023), against an average of $401470.6.
- The widest annual swing landed in 2022, when Current Leases plunged 96.06%; it then soared 2193.88% in 2025.
- A 5-year view of Current Leases shows it stood at $916000.0 in 2022, then tumbled by 94.32% to $52000.0 in 2023, then increased by 5.77% to $55000.0 in 2024, then slumped by 32.73% to $37000.0 in 2025, then jumped by 2151.35% to $833000.0 in 2026.
- The last three Current Leases figures came in at $833000.0 (Q1 2026), $37000.0 (Q4 2025), and $43000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Lineage Cell Therapeutics | 325.89 Mn | 261.99 Mn | 1.73 Mn | 833,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 833,000.00 |
| Dec 31, 2025 | 37,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 998,000.00 |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 46,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Sep 30, 2023 | 881,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Dec 31, 2022 | 916,000.00 |
| Sep 30, 2022 | 543,000.00 |
| Jun 30, 2022 | 29,000.00 |
| Mar 31, 2022 | 31,000.00 |
| Dec 31, 2021 | 801,000.00 |
| Sep 30, 2021 | 801,000.00 |
| Jun 30, 2021 | 17,000.00 |
| Mar 31, 2021 | 786,000.00 |
| Dec 31, 2020 | 16,000.00 |
| Sep 30, 2020 | 488,000.00 |
| Jun 30, 2020 | 1.24 Mn |
| Mar 31, 2020 | 1.24 Mn |
| Dec 31, 2019 | 1.22 Mn |
| Sep 30, 2019 | 1.14 Mn |
| Jun 30, 2019 | 956,000.00 |
| Mar 31, 2019 | 954,000.00 |
| Dec 31, 2018 | 237,000.00 |
| Sep 30, 2018 | 231,000.00 |
| Jun 30, 2018 | 225,000.00 |
| Mar 31, 2018 | 222,000.00 |
| Dec 31, 2017 | 212,000.00 |
| Dec 31, 2016 | 202,000.00 |
| Sep 30, 2016 | 173,000.00 |
| Jun 30, 2016 | 173,000.00 |
| Mar 31, 2016 | 22,000.00 |
| Dec 31, 2015 | 38,000.00 |
| Sep 30, 2015 | 46,000.00 |
| Jun 30, 2015 | 58,000.00 |
| Mar 31, 2015 | 57,500.00 |
| Dec 31, 2014 | 58,000.00 |
| Sep 30, 2014 | 57,500.00 |
| Jun 30, 2014 | 57,500.00 |